Roscovitine (Seliciclib): CDK Inhibitor Guide
2026-08-11
Roscovitine, also called Seliciclib or CYC202, is a selective cyclin-dependent kinase inhibitor used to study CDK signaling, cell-cycle control, and cancer biology. Its reported activity includes CDK2, CDK5, CDC2, and CDK7 inhibition, with reversible cell cycle arrest in late prophase and tumor growth inhibition in vivo.
GSK-923295: Practical CENP-E Assay Design
2026-08-10
This scenario-driven guide explains how GSK-923295, SKU A3450, can help researchers distinguish mitotic growth inhibition from nonspecific viability loss. It covers mechanism, dose planning, solvent handling, CTCF-related comparisons, data interpretation, and practical product-selection criteria for cancer research.
Light-Controlled RNA Release for Gene Therapy
2026-08-09
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. In mouse models, LIRP-enabled gene switches supported daylight-activated metabolic treatment and reversible retinal therapy, illustrating how optogenetics could add temporal control and safety to gene therapies.
Tp47, PKM2, and Inflammatory Senescence
2026-08-08
The reference study identifies a mechanistic link between the Treponema pallidum protein Tp47, PKM2-dependent metabolic reprogramming, and inflammatory senescence in macrophages. Its findings suggest that lactate production, EIF2AK2 phosphorylation, and NLRP3-associated pyroptotic signaling form an interconnected pathway that may help explain how syphilis alters host immune-cell function.
Ambroxol Targets Nav1.8, TRPV1, and TRPA1 in Pain
2026-08-07
This 2025 Journal of Pain study provides a mechanistic analysis of ambroxol at human and rat Nav1.8 channels and human TRPV1 and TRPA1 receptors. Its key contribution is to separate species-dependent sodium-channel inhibition from weaker, concentration-dependent modulation of irritant receptors, clarifying how topical ambroxol might influence neuropathic pain signaling.
Annexin V-PE Reagent (SKU K2280): Precision Apoptosis Detect
2026-08-07
This article delivers a scenario-driven, evidence-based guide for using Annexin V-PE Reagent (SKU K2280) to resolve key challenges in apoptotic cell detection workflows. Drawing on published research and workflow best practices, we detail how this Annexin V fluorescent conjugate from APExBIO enables reproducible, high-sensitivity assays for biomedical researchers. Protocol parameters, instrument compatibility, and vendor reliability are discussed in depth to optimize translational and basic laboratory experiments.
MAPK10 Phosphorylation of KRT16 Suppresses NSCLC Metastasis
2026-08-06
The referenced study delineates how mitogen-activated protein kinase 10 (MAPK10) phosphorylates keratin 16 (KRT16), inducing its ubiquitination and proteasomal degradation to suppress metastasis in non-small cell lung cancer (NSCLC). This mechanistic insight highlights the MAPK10/KRT16/RNF213 axis as a promising target for prognostic and therapeutic strategies in NSCLC.
Tropifexor (LJN452): Optimizing FXR Pathway & Barrier Resear
2026-08-06
Tropifexor (LJN452) from APExBIO is redefining FXR pathway studies with its unmatched potency and reproducibility in both metabolic and intestinal barrier research. This article provides actionable workflow enhancements, troubleshooting guidance, and protocol details for leveraging Tropifexor’s unique properties in advanced experimental models.
5X Protein Loading Buffer (Reducing): Technical Use and Best
2026-08-05
5X Protein Loading Buffer (Reducing) addresses the need for complete protein denaturation and disulfide bond reduction during SDS-PAGE. It is essential for workflows requiring accurate molecular weight-based separation of proteins, but should not be used in applications aiming to preserve native or non-reducing protein structures.
Biotin-XX Tyramide Reagent: Precision Cell Surface Protein P
2026-08-05
Biotin-XX Tyramide Reagent empowers high-sensitivity, membrane-impermeant cell surface protein labeling, unlocking robust tyramide signal amplification for immunohistochemistry and in situ hybridization. Its unique linker chemistry enables selective, covalent biotinylation for advanced proximity labeling workflows, setting a new standard for reproducibility and specificity.
SR-202: Redefining PPARγ Antagonism for Translational Metabo
2026-08-04
SR-202, a selective PPARγ antagonist, is emerging as a pivotal tool for dissecting the intricate interplay between metabolic and immune pathways in obesity, type 2 diabetes, and inflammatory diseases. This thought-leadership article guides translational researchers through the mechanistic rationale, experimental validation, and strategic application of SR-202, highlighting its unique role in bridging metabolic and immunological domains.
Etoposide (VP-16): Precision Tool for DNA Damage Assays
2026-08-04
Etoposide (VP-16) empowers researchers to probe DNA double-strand break pathways and apoptosis in cancer models with reproducible, quantitative control. This article delivers actionable workflows, comparative insights, and troubleshooting strategies—making it indispensable for advanced DNA damage and cancer chemotherapy research.
Fulvestrant (ICI 182,780): Applied Workflows for Breast Canc
2026-08-03
Fulvestrant (ICI 182,780) is a gold-standard tool for dissecting estrogen receptor signaling, MDM2 protein degradation, and overcoming endocrine therapy resistance in advanced breast cancer models. This guide delivers workflow enhancements, troubleshooting insights, and cross-domain applications grounded in the latest mechanistic findings.
Tropifexor (LJN452): FXR Modulation for Barrier & Metabolic
2026-08-03
Explore the mechanistic and translational significance of Tropifexor (LJN452), a potent FXR agonist, in advancing intestinal epithelial barrier function and metabolic disease research. This article offers scientific rationale, experimental validation, competitive insights, and strategic guidance for deploying Tropifexor in cutting-edge translational workflows, with context-rich evidence from recent neonatal piglet and organoid models.
AL-8810: Selective Prostaglandin F2α Antagonist for Research
2026-08-02
AL-8810 is a potent, selective prostaglandin F2α antagonist widely used to dissect FP receptor-mediated pathways. It enables precise modulation of vascular, endometrial, and smooth muscle signaling. Quantitative benchmarks and mechanistic insights support its role in advanced research on prostaglandin signaling.
460 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page